News for Halozyme Therapeutics, Inc. (0J2O.L)

The FDA has approved the VYVGART® Hytrulo prefilled syringe for self-injection, developed by argenx and co-formulated with Halozyme's ENHANZE® technology

Summary: Halozyme Therapeutics (HALO) receives European Commission approval for innovative multiple myeloma therapy. Analysts set a bullish one-year pric

Summary On April 9, 2025, Halozyme Therapeutics Inc (HALO) announced that the European Commission has approved an indication extension for DARZALEX® (daratumum

Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock is a Hold.

On March 3, 2025, Jeffrey Henderson, Director at Halozyme Therapeutics Inc (HALO), sold 5,000 shares of the company, according to a SEC Filing. Following this t

On February 27, 2025, Michael Labarre, Senior Vice President and Chief Technical Officer at Halozyme Therapeutics Inc (HALO), executed a sale of 21,697 shares o

Halozyme Therapeutics Inc (HALO), a leading biopharmaceutical company known for its innovative drug delivery solutions, announced on February 26, 2025, that its

PR NewswireSAN DIEGO, Feb. 26, 2025 SAN DIEGO, Feb. 26, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that D

Total Revenue: Exceeded $1 billion for the first time in 2024, growing 22% over the prior year.Royalty Revenue: Increased 27% to $571 million in 2024.Net Incom

Feb 18, 2025 / 09:30PM GMTOperator Good afternoon. My name is Karen, and I will be your conference moderator today. At this time, I would like to welcome everyo

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ETCompany ParticipantsTram Bui - Vice President,...

The following slide deck was published by Halozyme Therapeutics, Inc.

PR NewswireSAN DIEGO, Feb. 18, 2025 Fourth Quarter Total Revenue Increased 30% YOY to $298 million and Royalty Revenue Increased 40% YOY to $170 millionFou

Quarterly Revenue: $298 million, surpassing the estimated $288.24 million, marking a 30% increase year-over-year.Quarterly EPS: $1.06, slightly above the estim

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where Halozyme Therapeutics, Inc.

Biotechnology stocks are among the most volatile in the market due to their high risk.

Summary On February 3, 2025, Halozyme Therapeutics Inc (HALO) announced that Janssen-Cilag International NV, a Johnson & Johnson company, received a positive op

PR NewswireSAN DIEGO, Feb. 3, 2025 SAN DIEGO, Feb. 3, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janss

Halozyme Therapeutics Inc (HALO), a prominent biopharmaceutical company known for its innovative drug delivery solutions, announced on January 6, 2025, that it